Site Editor

Thomas Flaig, MD


Andrea B. Apolo, MD, on Practical Considerations of Using Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Cancer

Posted: Wednesday, February 7, 2024

Andrea B. Apolo, MD, of the National Cancer Institute, National Institutes of Health, discusses some of the issues to consider in light of her findings from the AMBASSADOR Alliance A031501 study, which showed adjuvant pembrolizumab improved disease-free survival vs observation for patients with high-risk muscle-invasive urothelial carcinoma after radical surgery.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.